Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immuneering (IMRX) Current Assets (2020 - 2024)

Immuneering has reported Current Assets over the past 5 years, most recently at $55.3 million for Q3 2024.

  • Quarterly results put Current Assets at $55.3 million for Q3 2024, down 45.06% from a year ago — trailing twelve months through Sep 2024 was $55.3 million (down 45.06% YoY), and the annual figure for FY2023 was $89.1 million, down 18.08%.
  • Current Assets for Q3 2024 was $55.3 million at Immuneering, down from $63.7 million in the prior quarter.
  • Over the last five years, Current Assets for IMRX hit a ceiling of $153.3 million in Q3 2021 and a floor of $37.7 million in Q4 2020.
  • Median Current Assets over the past 5 years was $100.6 million (2023), compared with a mean of $98.7 million.
  • Biggest five-year swings in Current Assets: surged 303.73% in 2021 and later plummeted 45.06% in 2024.
  • Immuneering's Current Assets stood at $37.7 million in 2020, then skyrocketed by 303.73% to $152.3 million in 2021, then fell by 28.61% to $108.7 million in 2022, then dropped by 18.08% to $89.1 million in 2023, then tumbled by 37.97% to $55.3 million in 2024.
  • The last three reported values for Current Assets were $55.3 million (Q3 2024), $63.7 million (Q2 2024), and $74.4 million (Q1 2024) per Business Quant data.